CADL · Candel Therapeutics
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $10.97
Note written ·
Price against the kill line
43.5% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $10.97, on record since 11 November 2026. The shares are down 49.0% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $10.97, which would more than erase the decline that followed the 12 November 2026 BLA delay and show the shares leading. A BLA submission announced before mid-2027 would also show the lag call failing.
Research onlyNot in the portfolio.
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 12 November 2026; valuation at the 13 November 2026 close
- Free cash flow, four quarters ($M)
- −70.2
- Net cash, cash less debt ($M)
- 202
- Free-cash-flow yield (%)
- −14.4
All filed numbers
What Candel Therapeutics reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −99.1 | −21.9 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +41.0 |
| Operating cash flow ($M) | −68.9 |
| Capital spending ($M) | 1.3 |
| Free cash flow ($M) | −70.2 |
| Cash and short-term investments ($M) | 203 |
| Debt ($M) other long-term debt | 1.1 |
| Net cash, cash less debt ($M) | 202 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 132 |
| Market value ($M) | 486 |
| Enterprise value, market value plus net debt ($M) | 284 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 3.7 |
| Free-cash-flow yield (%) | −14.4 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 16.3% of shares outstanding sold short, 14.1 days of average trading to cover, −1.8% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $0 | $3.2M |
| 12 monthsfrom | $3.0M | $3.6M |
The thesis
Candel Therapeutics' shares are more likely to lag the S&P 500 over the next three months. On 12 November 2026 the company moved its prostate-cancer biologics license application (BLA) for aglatimagene besadenovec from the fourth quarter of 2026 to mid-2027, and the shares closed at $8.39. A submission earlier than mid-2027 would show the shares leading; the full-year 2026 report, expected around March 2027, is the next scheduled check on the timetable.
The third-quarter 2026 release said the filing now depends on the company's dialogue with the US Food and Drug Administration (FDA) and on assay refinement timelines. The release also extended the cash runway to the second quarter of 2028. The Phase 3 result is unchanged, but the single event the case rested on has moved by roughly two quarters.
The market reaction was immediate. The shares closed at $9.22 on 11 November 2026 and at $8.39 on 12 November 2026, the session of the release. That close is level with the 200-day average of $8.4 and below the 50-day average of $9.89.
Bullish and bearish views on Candel Therapeutics, Inc.
The bull case on Candel Therapeutics, Inc. (CADL), in brief: the pivotal trial was positive. The bear case: the filing slipped by about two quarters.
Bull case
- The pivotal trial was positive. The Phase 3 prostate trial (n=745) met its primary endpoint with a disease-free survival hazard ratio of 0.70 (95% confidence interval 0.52–0.94, p=0.016), published in The Lancet Oncology on 2 June 2026.
- Cash covers a longer runway. Cash and equivalents were $203.1 million at 30 September 2026, against $119.7 million at 31 December 2025, and the company says the cash funds operations into the second quarter of 2028 (third-quarter 2026 release, 12 November 2026). The earlier guide was the first quarter of 2028.
- The quarterly loss narrowed. Third-quarter 2026 loss per share was $(0.28), against a $(0.35) estimate (company news, 12 November 2026). The net loss was $21.9 million, against $38.9 million in the second quarter, which carried $12.2 million of mostly warrant-related other expense.
- A second program and a launch partner exist. The first clinical site of the global Phase 3 AURORA trial in metastatic non-squamous lung cancer has been initiated (12 November 2026 release). A commercialization agreement with EVERSANA, announced 29 April 2026, supports a potential US launch.
Bear case
- The filing slipped by about two quarters. The 12 November 2026 release gives mid-2027 for the BLA, conditional on FDA dialogue and assay refinement. The plan stood at the fourth quarter of 2026 as recently as the 13 August 2026 results release.
- The shares fell on the day. The close of $8.39 on 12 November 2026 compares with $9.22 on 11 November 2026. The close is 40.1% below the $14.00 intraday 52-week high of 27 August 2026, and the three-month change is −28.4%.
- An at-the-market sales program adds supply. On 12 November 2026 the company signed a second amended open market sale agreement with Jefferies LLC covering up to $50 million of common shares, at a 3% commission, with sale prices set at execution.
- Insiders sold into the August–September rally. Chief Executive Officer Paul Tak sold 280,245 shares at an average of $11.28 on 10 September to 11 September 2026 under a Rule 10b5-1 plan (Form 4 filed 11 September 2026). Chief Technology Officer Seshu Tyagarajan sold 7,000 shares at $12.00 on 17 August 2026 under a plan (Form 4 filed 19 August 2026).
- Spending is rising ahead of revenue. Third-quarter research and development was $15.6 million against $8.5 million a year earlier. Nine-month net loss was $69.6 million against $8.7 million, and quarterly interest expense was $1.6 million against $0.2 million (12 November 2026 release).
- Regulatory reception is open. The upper end of the hazard-ratio interval is 0.94, and a legacy data-integrity matter tied to former leadership bears on how the FDA receives a filing.
Price setup
The shares closed at $8.39 on 12 November 2026. The 200-day average is $8.4 and the 50-day average is $9.89, so the shares moved from above the 50-day average to below it within the week. The closes of the week were $8.04 on 5 November 2026, $8.75 on 6 November 2026, $9.49 on 9 November 2026, $9.35 on 10 November 2026 and $9.22 on 11 November 2026.
The 52-week high is $14.00 (intraday, 27 August 2026). The 52-week closing low is $4.42 on 19 November 2025, set before the Phase 3 result.
The market has already moved the shares down by a little under a tenth in the session of the delay, and the stock has lost 28.4% over three months. The price reflects the slip to mid-2027 and the extended runway; the sales program's use is not yet disclosed. A single session's reaction is one observation and supports no wider conclusion about how the shares respond to timetable news.
Catalysts ahead
- ~12 March 2027 (est.): Fourth-quarter and full-year 2026 results. Updates the mid-2027 BLA timetable, cash against the runway into the second quarter of 2028 and any shares sold under the at-the-market program. The date is estimated from the 12 March 2026 filing of last year's report.
- ~June 2027 (est.): Planned BLA submission for aglatimagene in localized prostate cancer. The company's own date for the filing that the case rests on; a further delay would extend the lag, and an earlier submission would show the shares leading.
- ~August 2027 (est.): FDA filing-acceptance decision, about 60 days after a mid-2027 submission. Acceptance would be the first regulatory validation of the dataset; the legacy data-integrity matter is a risk to it.
What would change the view
A daily close above $10.97, which would more than erase the decline that followed the 12 November 2026 BLA delay and show the shares leading. A BLA submission announced before mid-2027 would also show the lag call failing.
What it trades with
Candel trades on its own regulatory timetable more than on sector moves. The 12 November 2026 session shows the shares reacting to a company-specific timetable change. The company is a single-asset, pre-revenue biotech, so a filing date, an FDA acceptance decision or a financing is the kind of event that moves it. Other small oncology and gene-therapy developers share funding-market sensitivity, but no peer series is cited here, and one dated reaction is too small a sample to measure correlation.
The evidence, claim by claim (7)
- Pivotal prostate Phase 3 met its primary endpoint: disease-free survival hazard ratio 0.70 (95% CI 0.52–0.94, p=0.016), n=745. The Lancet Oncology publication, 2 June 2026 · as of
- Company plans to submit the aglatimagene prostate-cancer BLA in mid-2027, dependent on FDA dialogue and assay refinement timelines; the earlier plan was the fourth quarter of 2026. Third-quarter 2026 results release (8-K Exhibit 99.1), 12 November 2026 · as of
- Cash and equivalents $203.1 million at 30 September 2026 versus $119.7 million at 31 December 2025; runway guided into the second quarter of 2028. Third-quarter 2026 results release, 12 November 2026 · as of
- Third-quarter 2026 net loss $21.9 million, loss per share $(0.28); research and development $15.6 million versus $8.5 million a year earlier; nine-month net loss $69.6 million versus $8.7 million. Third-quarter 2026 results release, 12 November 2026 · as of
- Second amended open market sale agreement with Jefferies LLC for up to $50 million of common shares, 3% commission, signed 12 November 2026. Form 8-K Exhibit 1.1, 12 November 2026 · as of
- Chief Executive Officer Paul Tak sold 280,245 shares at an average of $11.28 on 10 September to 11 September 2026 under a Rule 10b5-1 plan, after exercising 125,000 options at $1.55. SEC Form 4 filed 11 September 2026 · as of
- Late-breaking poster (abstract 1172) from the Phase 2 PrTK05 trial presented on immune profiling, biodistribution and viral shedding of aglatimagene besadenovec. SITC 41st Annual Meeting; company release 7 November 2026 · as of
Sources
Related · shared themes
SMMT
Summit Therapeutics
Summit Therapeutics' case rests on FDA approval of ivonescimab in EGFR-mutant lung cancer by the 14 November 2026 goal date. The agency's…
ZLAB
Zai Lab
Zai Lab's shares are modestly more likely to beat the S&P 500 over three months on zoci, its DLL3 cancer drug with an 81.8% first-line…
SLS
SELLAS Life Sciences Group
SELLAS Life Sciences is more likely to lag the S&P 500 over three months: its value rests on one Phase 3 leukemia trial, REGAL, whose…
CORT
Corcept Therapeutics
Corcept Therapeutics' Lifyorli launch is compounding ($91.4 million in Q3 2026, up from $47.6 million in Q2), yet the shares sit near their…
See also · stocks to watch